Autoimmune adverse event following COVID-19 vaccination in Seoul, South Korea - 05/06/24
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Background |
There is growing evidence that the coronavirus disease 2019 (COVID-19) vaccination can affect the regulation of the immune system, leading to the development of autoimmune diseases. However, the autoimmune adverse events (AEs) after COVID-19 vaccination remain largely unclear.
Objective |
We sought to investigate the autoimmune AEs after COVID-19 vaccination from a population-based cohort in South Korea.
Methods |
A total of 4,203,887 participants, representing 50% of the population residing in Seoul, were recruited from the National Health Insurance Service database and then divided into 2 groups on the basis of COVID-19 vaccination. The cumulative incidence, hazard ratios (HRs), and 95% CIs of autoimmune AEs were assessed following COVID-19 vaccination.
Results |
The incidence of vitiligo has been observed to be significantly higher in the vaccination group compared with the no vaccination group. The cumulative incidence of vitiligo began to show a significant difference starting 2 weeks after vaccination, and it reached 2.2% in the vaccination group and 0.6% in the no vaccination group by 3 months after COVID-19 vaccination. Vitiligo (HR, 2.714; 95% CI, 1.777-4.146) was an increased risk among autoimmune AEs. Furthermore, the risk of vitiligo was the highest for heterologous vaccination (HR, 3.890; 95% CI, 2.303-6.573) compared with using cDNA vaccine (HR, 2.861; 95% CI, 1.838-4.453) or mRNA vaccine (HR, 2.475; 95% CI, 1.607-3.813).
Conclusions |
Vitiligo as an autoimmune AE was noted to be substantially higher in the COVID-19–vaccinated group compared with the controls. Therefore, the occurrence of vitiligo could be considered as one of the significant AEs post–COVID-19 vaccination.
Le texte complet de cet article est disponible en PDF.Key words : COVID-19, vaccination, vitiligo, autoimmune adverse events, complications
Abbreviations used : AE, AIH, AS, CCI, COPD, COVID-19, DC, DM, GSEA, GTEx, HPA, HR, HT, HTN, IBD, IRB, NHIS, OR, PBC, RA, SARS-CoV-2
Plan
Vol 153 - N° 6
P. 1711-1720 - juin 2024 Retour au numéro
Article précédent
- Validating inborn error of immunity prevalence and risk with nationally representative electronic health record data
- Nicholas L. Rider, Ahuva Truxton, Tracy Ohrt, Irene Margolin-Katz, Mary Horan, Harold Shin, Roger Davila, Vanessa Tenembaum, Jessica Quinn, Vicki Modell, Fred Modell, Jordan S. Orange, Almut Branner, Cynthia Senerchia
- Joint transcriptomic and cytometric study of children with peanut allergy reveals molecular and cellular cross talk in reaction thresholds
- Lingdi Zhang, Yoojin Chun, Zoe Arditi, Galina Grishina, Tracy Lo, Kayla Wisotzkey, Charuta Agashe, Alexander Grishin, Julie Wang, Hugh A. Sampson, Scott Sicherer, M. Cecilia Berin, Supinda Bunyavanich
Bienvenue sur EM-consulte, la référence des professionnels de santé.